Sir-We would like to address Dr. Iseman's concern [1] that our study [2] may be misleading. Dr. Iseman expresses his concern by emphasizing the absence of evidence that slow conversion of sputum smear results from positive to negative status is associated with an increased risk for transmission of Mycobacterium tuberculosis, treatment failure, and acquired drug resistance so long as appropriate therapy is maintained.
We wish to stress that the patients in our study were expectorating high concentrations of viable organisms for months on end. Even in the absence of published evidence to the contrary, we would consider it cavalier to assume that such patients did not pose a risk to others in the community. Where the reader may be misled is in assuming that our study proved that our intervention prevented transmission. We do, however, respectfully suggest that the absence of positive stain and culture results for many months is somewhat reassuring.
Whether the patients in our study had "treatment failure" depends on the definition of the term. We do not dispute that, for many patients with multidrugresistant tuberculosis, positive sputum smear results ultimately convert to negative when the patients receive only conventional therapy. Unfortunately, the prolonged interval of sputum smear positivity and the requirement for protracted therapy, with the attendant problems of infectiousness, poor compliance, and development of drug resistance, are part of a global failure of tuberculosis management, if not a failure in the treatment of specific individuals. Although our intention was not to promote the use of aerosol therapy on the basis of our very preliminary evidence, we believe that the disruption to patients' lives and the expense that occur as a result of this intervention (if it is confirmed to be effective in future studies) compete favorably with the punitive and costly isolation requirements supported by the Centers for Disease Control and Prevention (Atlanta) for patients with tuberculosis who have persistently positive sputum smear results [3] .
We did not in any way wish to imply that aerosol therapy should be considered a substitute for systemic therapy. For no patient was traditional treatment abandoned once sterilization of secretions in the airways was achieved. We fully agree that aerosol therapy is unlikely to have any impact on organisms that are buried in the lymphatic system and the walls of the airways. However, we suggest that the presence of viable organisms in sputum is not cosmetic and that it represents a visible component of the infection. If viable organisms are expectorated via the airways, the airways presumably lead back to a source of these organisms. We are not advocating that treatment of systemic foci be discarded in favor of eradication of organisms from the sputum. We believe that both are components of a successful therapeutic regimen. The treatment of tuberculosis is complicated by problems with drug delivery to poorly vascularized tissues, fibrotic cavities, and calcified granulomas. Aerosol delivery offers a credible ancillary approach as part of a multipronged attack on the infection.
Dr. Iseman's failure to demonstrate ventilation in areas of chronic cavitary tuberculosis is not surprising. The rigid and distorted anatomy of these lesions prevents them from participating in normal ventilation. Gradual diffusion from communicating airways may allow for the entry of aerosolized antibiotics, and appropriate studies would be required to investigate the distribution of these agents in the lesions of tuberculosis.
It is with some reserve that we have considered the use of aerosol aminoglycoside therapy to be of benefit in patients with multidrug-resistant tuberculosis. Wherever possible, у5 drugs to which the organism was susceptible were used for each patient. Aerosol therapy was added when no additional treatment options were available. Even with the use of adjunctive aerosol aminoglycosides, responses were poor.
Finally, we applaud Dr. Iseman's skepticism. His skepticism serves to emphasize our view that the evidence from our small study is far too preliminary to be the basis for any practical recommendations. Much more robust data on the use of aerosol aminoglycosides and other aerosolized antituberculous medications are required before clinicians should consider using this treatment modality in clinical practice. 
Ciprofloxacin for Treatment of Tularemia
Sir-Limaye and Hooper [1] reported successful treatment of typhoidal bacteremic tularemia with levofloxacin in 2 immunocompromised adults, and they reviewed another 8 cases of tularemia in which a favorable response to quinolones had been documented. In apparent contradiction, Chocarro et al. [2] reported relapse in 7 of 14 patients who were treated with ciprofloxacin at a dosage of 500-750 mg b.i.d. for 10-28 days. It should be noted, however, that, in the latter report, the interval between onset of disease and start of treatment with ciprofloxacin was not specified, and, in 4 of 7 cases with relapse, ciprofloxacin was used as a secondary therapy.
We recently reported successful treatment of ulceroglandular tularemia with oral ciprofloxacin in 12 pediatric patients [3] . Here we report additional data from an outbreak of this disease in 1998 in central Sweden, where 43 patients (median age, 51 years; range, 21-83 years) were treated primarily with oral ciprofloxacin. Diagnosis was confirmed by use of serological tests and/or culture, and in 11 cases also by use of PCR, all performed according to methods described elsewhere [4] . For 41 of the 43 patients (24 with ulceroglandular, 3 with pulmonary, and 14 with typhoidal tularemia), the response to ciprofloxacin at a dosage of 500-750 mg b.i.d. for 10 days was excellent and no complications or relapse occurred.
For these patients, the mean interval from onset of disease to initiation of ciprofloxacin therapy was 3.7 days (median, 3 days; range, 0-14 days). Two patients experienced complications. One patient, who presented 5 days after onset of typhoidal/pulmonary tularemia, responded well to a 10-day course of ciprofloxacin but relapsed 7 days after the end of treatment, with fever, arthralgia, and a pulmonary infiltrate. For another patient, treatment with ciprofloxacin was initiated 3 weeks after the onset of ulceroglandular tularemia; 20 days later, a lymph node abscess developed.
With respect to new options for the treatment of tularemia, conclusions should be based mainly on results from primary use of a drug. For patients who have previously received a course of treatment with another drug, the evaluation is more difficult. Moreover, in cases where there is considerable delay before initiation of treatment, the development of lymph node abscesses or other complications may no longer be prevented by antibiotic agents that are appropriate for Francisella tularensis [5] . Previous reports on clinical use of quinolones [1, 3] and the present data, together with in vitro assays showing that quinolones have MIC values well below 0.1 mg/ml [3, 6, 7] and have in vivo efficacy with experimentally induced tularemia [8] , argue strongly for the use of quinolones as alternative agents for the treatment of tularemia. 
